Interim results report 94% efficacy with Moderna/NIH mRNA vaccine: FDA hearing on 17 December
On 16 November 2020, a press statement from the UK NIH (a partner with Moderna for the mRNA-1273 vaccine) announced 94% efficacy in an interim analysis from the ongoing phase 3 COVE study. 
The results, released from the trial’s Data and Safety Monitoring Board (DSMB) reported 95 cases of symptomatic infection: 90 vs 5 cases in the placebo vs vaccine groups, respectively.
Additionally, all 11/95 cases of severe COVID-19 were in placebo recipients.
The study was launched on 27 July 2020 and has enrolled 30,000 participants at 100 sites in the US. 
The FDA advisory committee hearing for this vaccine is due on 17 December 2020. Meeting amterials are posted online and the hearing is webcast. 
- NIH press statement. Promising interim results from clinical trial of NIH-Moderna COVID-19 Vaccine/ (16 November 2020).
- clinicaltrials.gov. A study to evaluate efficacy, safety, and immunogenicity of mRNA-1273 vaccine in adults aged 18 years and older to prevent COVID-19.
- Vaccines and related biological products advisory committee: December 17, 2020 meeting announcement.